136 related articles for article (PubMed ID: 38874541)
1. Targeting Tuberculosis: Novel Scaffolds for Inhibiting Cytochrome
Seitz C; Ahn SH; Wei H; Kyte M; Cook GM; Krause KL; McCammon JA
J Chem Inf Model; 2024 Jun; ():. PubMed ID: 38874541
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Biological Evaluation of Aurachin D Analogues as Inhibitors of
Lawer A; Tyler C; Hards K; Keighley LM; Cheung CY; Kierek F; Su S; Matikonda SS; McInnes T; Tyndall JDA; Krause KL; Cook GM; Gamble AB
ACS Med Chem Lett; 2022 Oct; 13(10):1663-1669. PubMed ID: 36262396
[TBL] [Abstract][Full Text] [Related]
3. Syntheses and Structure-Activity Relationships of
Hopfner SM; Lee BS; Kalia NP; Miller MJ; Pethe K; Moraski GC
Appl Sci (Basel); 2021 Oct; 11(19):. PubMed ID: 36698770
[TBL] [Abstract][Full Text] [Related]
4. Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis.
Foo CS; Lupien A; Kienle M; Vocat A; Benjak A; Sommer R; Lamprecht DA; Steyn AJC; Pethe K; Piton J; Altmann KH; Cole ST
mBio; 2018 Oct; 9(5):. PubMed ID: 30301850
[TBL] [Abstract][Full Text] [Related]
5. Novel targets and inhibitors of the
Harikishore A; Mathiyazakan V; Pethe K; Grüber G
Expert Opin Drug Discov; 2023; 18(8):917-927. PubMed ID: 37332221
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 1-hydroxy-2-methylquinolin-4(1H)-one derivatives as new cytochrome bd oxidase inhibitors for tuberculosis therapy.
Zhou Y; Shao M; Wang W; Cheung CY; Wu Y; Yu H; Hu X; Cook GM; Gong H; Lu X
Eur J Med Chem; 2023 Jan; 245(Pt 1):114896. PubMed ID: 36370551
[TBL] [Abstract][Full Text] [Related]
7. New inhibitors of the quinol oxidation sites of bacterial cytochromes bo and bd.
Meunier B; Madgwick SA; Reil E; Oettmeier W; Rich PR
Biochemistry; 1995 Jan; 34(3):1076-83. PubMed ID: 7827023
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome
Saha P; Das S; Indurthi HK; Kumar R; Roy A; Kalia NP; Sharma DK
RSC Med Chem; 2024 Mar; 15(3):769-787. PubMed ID: 38516593
[TBL] [Abstract][Full Text] [Related]
9. The cytochrome bd-type quinol oxidase is important for survival of Mycobacterium smegmatis under peroxide and antibiotic-induced stress.
Lu P; Heineke MH; Koul A; Andries K; Cook GM; Lill H; van Spanning R; Bald D
Sci Rep; 2015 May; 5():10333. PubMed ID: 26015371
[TBL] [Abstract][Full Text] [Related]
10. Structure guided generation of thieno[3,2-
Hopfner SM; Lee BS; Kalia NP; Miller MJ; Pethe K; Moraski GC
RSC Med Chem; 2021 Jan; 12(1):73-77. PubMed ID: 34046599
[TBL] [Abstract][Full Text] [Related]
11. Structure of Escherichia coli cytochrome bd-II type oxidase with bound aurachin D.
Grauel A; Kägi J; Rasmussen T; Makarchuk I; Oppermann S; Moumbock AFA; Wohlwend D; Müller R; Melin F; Günther S; Hellwig P; Böttcher B; Friedrich T
Nat Commun; 2021 Nov; 12(1):6498. PubMed ID: 34764272
[TBL] [Abstract][Full Text] [Related]
12. Data for molecular dynamics simulations of
Ahn SH; Seitz C; Cruzeiro VWD; McCammon JA; Götz AW
Data Brief; 2021 Oct; 38():107401. PubMed ID: 34621930
[TBL] [Abstract][Full Text] [Related]
13. The anti-mycobacterial activity of the cytochrome bcc inhibitor Q203 can be enhanced by small-molecule inhibition of cytochrome bd.
Lu P; Asseri AH; Kremer M; Maaskant J; Ummels R; Lill H; Bald D
Sci Rep; 2018 Feb; 8(1):2625. PubMed ID: 29422632
[TBL] [Abstract][Full Text] [Related]
14. Host immunity increases Mycobacterium tuberculosis reliance on cytochrome bd oxidase.
Cai Y; Jaecklein E; Mackenzie JS; Papavinasasundaram K; Olive AJ; Chen X; Steyn AJC; Sassetti CM
PLoS Pathog; 2021 Jul; 17(7):e1008911. PubMed ID: 34320028
[TBL] [Abstract][Full Text] [Related]
15. Terminal Respiratory Oxidases: A Targetables Vulnerability of Mycobacterial Bioenergetics?
Bajeli S; Baid N; Kaur M; Pawar GP; Chaudhari VD; Kumar A
Front Cell Infect Microbiol; 2020; 10():589318. PubMed ID: 33330134
[TBL] [Abstract][Full Text] [Related]
16. Targeting the menaquinol binding loop of mycobacterial cytochrome bd oxidase.
Harikishore A; Chong SSM; Ragunathan P; Bates RW; Grüber G
Mol Divers; 2021 Feb; 25(1):517-524. PubMed ID: 31939065
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of (Quinazoline 4-yloxy)acetamide and (4-oxoquinazoline-3(4H)-yl)acetamide derivatives as inhibitors of Mycobacterium tuberculosis bd oxidase.
Kumar A; Kumari N; Bhattacherjee S; Venugopal U; Parwez S; Siddiqi MI; Krishnan MY; Panda G
Eur J Med Chem; 2022 Nov; 242():114639. PubMed ID: 35973312
[TBL] [Abstract][Full Text] [Related]
18. Short-chain aurachin D derivatives are selective inhibitors of E. coli cytochrome bd-I and bd-II oxidases.
Radloff M; Elamri I; Grund TN; Witte LF; Hohmann KF; Nakagaki S; Goojani HG; Nasiri H; Hideto Miyoshi ; Bald D; Xie H; Sakamoto J; Schwalbe H; Safarian S
Sci Rep; 2021 Dec; 11(1):23852. PubMed ID: 34903826
[TBL] [Abstract][Full Text] [Related]
19. Identification of 2-Aryl-Quinolone Inhibitors of Cytochrome
Jeffreys LN; Ardrey A; Hafiz TA; Dyer LA; Warman AJ; Mosallam N; Nixon GL; Fisher NE; Hong WD; Leung SC; Aljayyoussi G; Bibby J; Almeida DV; Converse PJ; Fotouhi N; Berry NG; Nuermberger EL; Upton AM; O'Neill PM; Ward SA; Biagini GA
ACS Infect Dis; 2023 Feb; 9(2):221-238. PubMed ID: 36606559
[No Abstract] [Full Text] [Related]
20. SAR and identification of 2-(quinolin-4-yloxy)acetamides as
Phummarin N; Boshoff HI; Tsang PS; Dalton J; Wiles S; Barry Rd CE; Copp BR
Medchemcomm; 2016 Nov; 7(11):2122-2127. PubMed ID: 28337336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
